NCT04561206View on ClinicalTrials.gov

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

November 12, 2021

Primary Completion Date

October 2, 2026

Study Completion Date

October 2, 2026

Conditions
Relapsed Classic Hodgkin Lymphoma
Interventions
DRUG

Brentuximab Vedotin

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (5)

37203

RECRUITING

Sarah Cannon Research Institute, Nashville

60637

RECRUITING

University of Chicago Cancer Research Center, Chicago

91010

RECRUITING

City of Hope Medical Center, Duarte

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

07601

RECRUITING

Hackensack University Medical Center/John Theurer Cancer Center, Hackensack

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER